AGEN

Companies
NASDAQ
Agenus Inc.
Health Care
Price Chart
Overview

About AGEN

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Market Cap
$348.6M
Volume
2.1M
Avg. Volume
2.3M
P/E Ratio
-0.15583076
Dividend Yield
0.00%
Employees
348.0

Company Information

Exchange
NASDAQ
Sector
Health Care
Industry
Biotechnology
Risk & Correlation Analysis
Market Correlation
1.70
High Correlation
Volatility
High (1.00)
Relative to market

Macro Factor Sensitivities

Interest Rates
Low Sensitivity
Inflation
Medium Sensitivity
GDP Growth
High Sensitivity
Liquidity
High Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for AGEN.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, AGEN shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$348.6M
Volume2.1M
P/E Ratio-0.16
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
March 11, 2025

PortfolioPilot Analysis

Get AI-powered insights on how AGEN fits into your investment strategy and portfolio diversification.

Pricing info last updated June 17, 2025 (after market close)Other info last updated April 2, 2025